CareDx发布Alloheme™临床验证结果:首款用于AML及MDS细胞疗法后监测的AI驱动NGS解决方案

美股速递
Feb 12

CareDx公司宣布了其创新产品Alloheme™的临床验证结果。该产品是首款结合人工智能技术的下一代测序监测解决方案,专为急性髓系白血病和骨髓增生异常综合征患者在细胞治疗后的病情监控而设计。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10